In men aged 50 years and over with visceral obesity and impaired glucose tolerance, testosterone treatment on the background of a lifestyle intervention reduced T2D risk by 40%, though results vary across trials due to differences in design, age groups, and outcome measures.
Key Findings
Results
The T4DM trial showed testosterone treatment reduced type 2 diabetes risk by 40% in high-risk men over 2 years.
The 2-year Testosterone for the Prevention of Type 2 Diabetes Mellitus (T4DM) study was the primary source of this finding.
Participants were men aged 50 years and over with visceral obesity and impaired glucose tolerance.
Testosterone treatment was administered on the background of a lifestyle intervention.
The risk reduction was 40% compared to placebo plus lifestyle intervention.
Results
The Testosterone Effects on Atherosclerosis Progression in Aging Men and Testosterone Trials demonstrated modest improvements in insulin sensitivity and body composition.
These trials are distinct from the T4DM study and involved different populations and designs.
Improvements were characterized as 'modest' in insulin sensitivity.
Body composition improvements were also observed in these trials.
These findings are contrasted with the more pronounced glycemic outcomes in T4DM.
Results
The TRAVERSE trial found no significant glycemic benefits of testosterone replacement therapy over 2 years.
The trial full name is Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE).
The study duration was 2 years.
No significant glycemic benefits were found, in contrast to the T4DM trial findings.
Differences in trial design, age groups, and outcome measures are cited as contributing to the differing results.
Discussion
HbA1C is identified as a suboptimal outcome measure for trials investigating testosterone's effects on glycemic control.
This finding is noted as a methodological consideration relevant to interpreting varying trial results.
The authors suggest this contributes to inconsistencies across studies.
The implication is that other glycemic outcome measures may be more appropriate in future research.
Results
Recent data from the Diabetes Prevention Program Outcome Study support the cost efficacy and durability of metformin for T2D prevention.
The Diabetes Prevention Program Outcome Study (DPPOS) provided the supporting data.
Both cost-effectiveness and long-term durability of metformin are highlighted.
This is presented as an alternative or comparator approach to testosterone treatment for high-risk men.
The authors note that 'other approaches may be more applicable' than testosterone in some cases.
Discussion
Future research should explore potential synergies between testosterone and GLP-1 receptor agonists in T2D management.
This recommendation reflects the emerging role of GLP-1 receptor agonists in obesity and diabetes treatment.
Cost-effectiveness is identified as an important consideration alongside potential synergies.
The suggestion implies neither testosterone nor GLP-1 agonists alone may be optimal for all patients.
This is framed as a gap in current evidence requiring future investigation.
Discussion
Differences in trial designs, age groups, and outcome measures contribute to varying results across testosterone and glycemic control trials.
This finding is offered as an explanation for the inconsistent results across the T4DM, TRAVERSE, and Testosterone Trials.
Age groups are specifically cited as a variable that differs meaningfully between studies.
Outcome measures, including the noted suboptimality of HbA1C, are identified as a source of variability.
Trial design differences are also highlighted as contributing to discordant findings.
Wittert G, Umapathysivam M. (2024). Testosterone and the prevention of type 2 diabetes mellitus: therapeutic implications from recent trials.. Current opinion in endocrinology, diabetes, and obesity. https://doi.org/10.1097/MED.0000000000000884